← Leaderboards
Mitchell L Shiffman
Virginia Commonwealth University
$2,507,516
Attributed
$2,507,516
Total exposure
26
Grants
9
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $402.2K · FY2005–10$500K$375K$250K$125K$0
'05
'06
'07
'08
'09
'10
Funding mix
By agency
NIH$2,507,516 · 26
By mechanism
M01$1,808,733 · 25
N01$698,783 · 1
Top collaborators
No co-investigators on record.
Most similar at Virginia Commonwealth University
Same institution · by research overlap
- Richard K. Sterling$9,383,090
- Arun J Sanyal$37,042,537
- Velimer A Luketic$648
- Bin Gao$700,617
- Robert A Fisher$4,942,616
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHepatitis CHuman SubjectHuman Therapy EvaluationHepatitis C VirusRibavirinInterferonsLiver Disorder ChemotherapyClinical TrialsInterferon AlphaImmunotherapyDrug Screening /EvaluationFibrosisOutcomes ResearchCombination ChemotherapyLiver TransplantationAntiviral AgentsInstitutionResourcesComputer Retrieval Of Information On Scientific Projects DatabasePathologic ProcessFundingGrantResearch Personnel
Grant awards (39)
ANCILLARY STUDY TO THE HALT-C ANTI-VIRAL LONG-TERM TREATMENT AGAINST CIRRHOSI$1,289
M01 · FY2010 · RR · contact PI
CLINICAL TRIAL: HEP C ANTIVIRAL LONG-TERM TREATMENT AGAINST CIRRHOSIS (HALT-C)$196,411
M01 · FY2009 · RR · contact PI
ANCILLARY STUDY TO THE HALT-C ANTI-VIRAL LONG-TERM TREATMENT AGAINST CIRRHOSI$466
M01 · FY2009 · RR · contact PI
CLINICAL TRIAL: HEP C ANTIVIRAL LONG-TERM TREATMENT AGAINST CIRRHOSIS (HALT-C)$213,512
M01 · FY2008 · RR · contact PI
QUANTITATIVE ASSESSMENT OF HEPATIC FUNCTION IN CHRONIC HEPATITIS C$20,100
M01 · FY2008 · RR · contact PI
HEP C ANTIVIRAL LONG-TERM TREATMENT AGAINST CIRRHOSIS (HALT-C) TRIAL$250,368
M01 · FY2007 · RR · contact PI
QUANTITATIVE ASSESSMENT OF HEPATIC FUNCTION IN CHRONIC HEPATITIS C$48,459
M01 · FY2007 · RR · contact PI
HEP C ANTIVIRAL LONG-TERM TREATMENT AGAINST CIRRHOSIS (HALT-C) TRIAL$238,086
M01 · FY2006 · RR · contact PI
QUANTITATIVE ASSESSMENT OF HEPATIC FUNCTION IN CHRONIC HEPATITIS C$28,772
M01 · FY2006 · RR · contact PI
HEP C ANTIVIRAL LONG-TERM TREATMENT AGAINST CIRRHOSIS (HALT-C) TRIAL$303,395
M01 · FY2005 · RR
QUANTITATIVE ASSESSMENT OF HEPATIC FUNCTION IN CHRONIC HEPATITIS C$88,754
M01 · FY2005 · RR
NATURAL HISTORY OF CHRONIC HEP B &C AND THE EFFECTS OF ANTI-VIRAL THERAPY$10,027
M01 · FY2005 · RR
Hep C Antiviral Long-term Treatment Against Cirrhosis$338,195
M01 · FY2004 · RR
Natural History of Chronic Hep B &C and the Effects of Anti-Viral Therapy$53,347
M01 · FY2004 · RR
Assessment of Hepatic Function in Chronic Hepatitis C$10,317
M01 · FY2004 · RR
PEG Interferon plus Ribavirin for the treatment of HCV$755
M01 · FY2004 · RR
PROSPECTIVE RANDOMIZED CONTROLLED TRIAL TO DETERMINE IF REDUCTION IN$0
M01 · FY2001 · RR
OPTIMUM PATIENT POPULATION AND DOSING REGIMEN FOR TREAMENT OF HEPATITIS C$0
M01 · FY2001 · RR
EVALUATION OF GM-CSF FOR TREATMENT OF CHRONIC HCV$0
M01 · FY2001 · RR
NATURAL HISTORY, PREVENTION AND TREATMENT OF RECURRENT VIRAL HEPATITIS B &C$0
M01 · FY2001 · RR
METABOLIC LIVER FUNCTION TEST TO PREDICT MORBIDITY/MORTALITY IN LIVER CIRRHOSIS$0
M01 · FY2001 · RR
TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C WITH A COMBINATION OF INTERFERON$0
M01 · FY2001 · RR
TREATMENT OF CHRONIC HEPATITIS C W/ COMBINATION OF INTERFERON PLUS$0
M01 · FY2001 · RR
TX OF CHRONIC HEPATITIS C &INTERFERON PLUS RIBAVIRIN &TREATMENT NA$0
M01 · FY2001 · RR
MYCOPHENOLATE MOFETIL IN PRIMARY SCLEROSING CHOLANGITIS$0
M01 · FY2001 · RR
RANDOMIZED DBL BLIND PLACEBO CONTR DOSE ESCALATION STUDY W/ VX 497 I$0
M01 · FY2001 · RR
HEPATITIS C CLINICAL TRIAL- CLINICAL CENTERS$423,556
N01 · FY2000 · DK
HEPATITIS C CLINICAL TRIAL- CLINICAL CENTERS$275,227
N01 · FY2000 · DK
EVALUATION OF GM-CSF FOR TREATMENT OF CHRONIC HCV$648
M01 · FY2000 · RR
OPTIMUM PATIENT POPULATION AND DOSING REGIMEN FOR TREAMENT OF HEPATITIS C$648
M01 · FY2000 · RR
RANDOMIZED DBL BLIND PLACEBO CONTR DOSE ESCALATION STUDY W/ VX 497 I$648
M01 · FY2000 · RR
MYCOPHENOLATE MOFETIL IN PRIMARY SCLEROSING CHOLANGITIS$648
M01 · FY2000 · RR
TX OF CHRONIC HEPATITIS C &INTERFERON PLUS RIBAVIRIN &TREATMENT NA$648
M01 · FY2000 · RR
PROSPECTIVE RANDOMIZED CONTROLLED TRIAL TO DETERMINE IF REDUCTION IN$648
M01 · FY2000 · RR
TREATMENT OF CHRONIC HEPATITIS C W/ COMBINATION OF INTERFERON PLUS$648
M01 · FY2000 · RR
TREATMENT OF PATIENTS WITH CHRONIC HEPATITIS C WITH A COMBINATION OF INTERFERON$648
M01 · FY2000 · RR
METABOLIC LIVER FUNCTION TEST TO PREDICT MORBIDITY/MORTALITY IN LIVER CIRRHOSIS$648
M01 · FY2000 · RR
NATURAL HISTORY, PREVENTION AND TREATMENT OF RECURRENT VIRAL HEPATITIS B &C$648
M01 · FY2000 · RR
HISTORY OF CHRONIC HEPATITIS C AFTER LIVER TRANSPLANT$0
M01 · FY2000 · RR